🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study

Recruitingn/aAges 18 Years - anyAllSun Yat-sen University
NCT06801977 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This retrospective case-control study aims to investigate the genetic mechanisms of primary Pulmonary Lymphoepithelioma-like Carcinoma, identify genetic susceptibility loci associated with its onset, and explore potential pathogenic genes, providing new insights for its etiological research.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Case: Inclusion criteria: The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma. Exclusion criteria: The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease. Controls: Inclusion criteria: The subject is in good physical condition and has a stable level of consciousness; Exclusion criteria: The subject has prevalent cancer; The subject has heavy cardiovascular, liver, or kidney disease.
💊

What it tests

  • Genome-wide genotyping
📍

Where

2 sites
Foshan First People's Hospital
Foshan, China
Sun Yat-sen University Cancer Center
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy